Drug Profile
Rever3mab - Takis
Alternative Names: TK 003; TK-003MAbLatest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Takis
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB-3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 12 Sep 2023 Preclinical development is ongoing for Cancer in Italy (Parenteral) (Takis Biotech pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in Italy (Parenteral)
- 08 Jul 2016 Preclinical trials in Cancer in Italy (Parenteral)